PHP-201 is a kinase platform company focusing on ophthalmology and is developing new treatments for serious eye conditions. The Company's lead candidate, PHP-201, targets glaucoma, a condition which damages the optic nerve resulting in vision loss and ultimately blindness.
PHP-201 is based on its unique 'Localized Drug Action' platform which generates novel kinase inhibitors that minimize systemic exposure with the aim of reducing side effects.
Clinical stage asset acquired from AMAKEM NV in Feb 2016
Rho kinase (ROCK) inhibitor for treatment of Normal Tension Glaucoma (NTG), and potentially primary open angle glaucoma (POAG) and ocular hypertension (OHT)
Top clinical advisors recruited
Key differentiating feature: Reduction of Intraocular pressure (IOP) without inducing hyperemia (red eye) seen with other ROCK inhibitors and prostaglandins
MFDS approved in October 2016; Phase 2 clinical trial initiation in Korea 4Q 16
First choice option in NTG; more than 70% of Korean/Japanese market
Option for patients unable (resistance/intolerance) or unwilling (due to cosmetic side effects) to use prostaglandin analogs (PGAs)
Adjunctive therapy – to be used in addition to PGAs
PHP-201 is a differentiated ROCK inhibitor
Relaxes trabecular meshwork and reduces intra-ocular pressure (IOP)
Has demonstrated clinical proof-of-concept
Magnitude of IOP lowering effect is similar to ripasudil
Fast follow-on to Kowa’s ripasudil product without hyperemia